Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 425809 in Healthy Japanese and Chinese Male Subjects (Randomized, Double-blind, Placebo-controlled Design Within Dose Groups)
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2015
At a glance
- Drugs BI 425809 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 13 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 30 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 May 2015 Planned End Date changed from 1 Jun 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov